| " Crossing Jordan"--pleural mesothelioma evolving as a treatable disease W Eberhardt Pneumologie (Stuttgart, Germany) 58 (4), 208-209, 2004 | 1 | 2004 |
| “Minimal N2-disease”(operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase-III-trial of surgery (S) followed by adjuvant … W Eberhardt, S Korfee, H Wagner, G Stamatis, S Bildat, M Stuschke, ... Lung Cancer 1 (29), 95-96, 2000 | 6 | 2000 |
| “One-stop-shop” staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? T Heusner, P Gölitz, M Hamami, W Eberhardt, S Esser, M Forsting, ... European journal of radiology 78 (3), 430-435, 2011 | 65 | 2011 |
| „Zeit des Erwachens” oder „Was bedeuten die konkurrierenden Risiken beim nicht kleinzelligen Bronchialkarzinom für unsere interdisziplinären Therapiekonzepte”? W Eberhardt Pneumologie 56 (12), 765-767, 2002 | | 2002 |
| «Pillnitzer interdisziplinäres Gespräch»–Teilnehmer U Gatzemeier, F Griesinger, RM Huber, M Baumann, UCG Carus, ... | | 2006 |
| (68) GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC) N Hirmas, M Schuler, K Darwiche, WEE Eberhardt, C Aigner, M Stuschke, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 49 (SUPPL 1 …, 2022 | | 2022 |
| 10-YEAR LONG-TERM SURVIVAL (LTS) OF INDUCTION (IND) CHEMOTHERAPY (CTX) WITH THREE CYCLES CISPLATIN (P)/PACLITAXEL (T) FOLLOWED BY CONCURRENT (CC) CHEMORADIATION (CTX/RTX) P … C Poettgen, C Le Pechoux, TC Gauler, M Stuschke, DH Grunenwald, ... JOURNAL OF THORACIC ONCOLOGY 6 (6), S494-S494, 2011 | | 2011 |
| 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid … WEE Eberhardt, TC Gauler, C LePechoux, G Stamatis, S Bildat, T Krbek, ... Lung cancer 82 (1), 83-89, 2013 | 41 | 2013 |
| 1065 Results of a multimodality preoperative induction treatment program in locally advanced (LAD) NSCLC stages IIIA and IIIB W Eberhardt, H Wilke, G Stamatis, M Stuschke, H Menker, MR Müller, ... European Journal of Cancer 31, S222-S223, 1995 | 2 | 1995 |
| 1162P Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II … A Gröschel, B Passlick, M Stuschke, P Christopoulos, M Reck, C Grah, ... Annals of Oncology 32, S935-S936, 2021 | | 2021 |
| 1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315) M Sebastian, F Griesinger, E Von der Heyde, S Dörfel, JH Wiegand, ... Annals of Oncology 33, S1080-S1081, 2022 | | 2022 |
| 1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in … T Trarbach, J Drevs, D Strumberg, TC Gauler, V Schneider, WE Eberhardt, ... EJC Supplements 2 (7), 129, 2009 | | 2009 |
| 1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315) F Griesinger, M Sebastian, W Brückl, HD Hummel, B Jaeschke, J Kern, ... Annals of Oncology 32, S1015-S1016, 2021 | | 2021 |
| 1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C F Griesinger, WEE Eberhardt, P Hoffknecht, M Metzenmacher, T Wehler, ... Annals of Oncology 31, S872, 2020 | 1 | 2020 |
| 1388P Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315) F Griesinger, WEE Eberhardt, M Jaenicke, A Fleitz, P Ludwig, A Groth, ... Annals of Oncology 35, S870, 2024 | | 2024 |
| 1457P Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome M Wiesweg, C Küter, J Schnorbach, J Keyl, T Plönes, M Metzenmacher, ... Annals of Oncology 34, S828, 2023 | | 2023 |
| 15-YEAR (VERY) LONG-TERM SURVIVAL (VLTS) AND COMPETING RISKS (CR) ANALYSIS OF INDUCTION (IND) CHEMOTHERAPY (CTX) WITH THREE CYCLES CISPLATIN (P)/ETOPOSIDE (E) FOLLOWED BY … R Hepp, TC Gauler, C Poettgen, S Korfee, S Bildat, G Stamatis, S Seeber, ... JOURNAL OF THORACIC ONCOLOGY 6 (6), S492-S493, 2011 | | 2011 |
| 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) B Besse, M Johnson, PA Janne, M Garassino, WEE Eberhardt, S Peters, ... European Journal of Cancer 3 (51), S717-S718, 2015 | 94 | 2015 |
| 18 F-FDG-Response as a prognostic Factor for the progression free Survival in the Treatment of locally advanced, non-small cell Lung Carcinoma: Trimodal Therapy vs. definitive … M Guberina, M Stuschke, J Abu Jawad, T Gauler, E Gkika, A Bockisch, ... STRAHLENTHERAPIE UND ONKOLOGIE 191, S21-S22, 2015 | | 2015 |
| 1ST-CYCLE RASH AS A CLINICAL MARKER OF OUTCOME IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING 1ST-LINE CHEMOTHERAPY (CT) PLUS CETUXIMAB: ANALYSIS BY … K O'Byrne, J von Pawel, I Vynnychenko, W Eberhardt, F De Marinis, ... ANNALS OF ONCOLOGY 21, 131-132, 2010 | | 2010 |
Kaid Darwiche在 darwiche.de 的电子邮件经过验证
